BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

▤ Summary

BioRestorative Therapies completed manufacturing for its BRTX-100 Phase 2 clinical trial supply. The milestone supports continued development of its lead cell therapy for chronic lumbar disc disease. The company highlights its vertically integrated regenerative biologics platform, which spans cell sourcing, processing, formulation, and manufacturing. It also points to shared infrastructure that supports both therapeutic programs and commercial bio-cosmeceutical products. The release says this setup improves quality, scalability, and operating costs.

▦ Linked Companies